-
The Upstream and Downstream products of 3-Bromo-N-(phenylmethyl)benzenesulfonamide
Time of Update: 2023-05-09
The upstream and downstream products of the 3-bromo-N-(phenylmethyl)benzenesulfonamide manufacturing process must be carefully managed to ensure the quality of the final product.
The upstream and downstream products of the 3-bromo-N-(phenylmethyl)benzenesulfonamide manufacturing process must be carefully managed to ensure the quality of the final product.
-
The Production Process of Barnidipine hydrochloride
Time of Update: 2023-05-07
However, it is important to note that the production process of barnidipine hydrochloride involves several stages, including synthesis, purification, and formulation, and each of these stages must be carefully controlled to ensure the quality of the final product.
-
The Production Process of Bleomycin A5
Time of Update: 2023-05-01
The production process of bleomycin involves several steps, which are carefully controlled to ensure the quality and efficacy of the final product.
The production process of bleomycin involves several steps, which are carefully controlled to ensure the quality and efficacy of the final product.
-
Meigang Steel Mill promotes cable repair
Time of Update: 2022-11-23
cable After a two-month trial of the cable repaired according to the new standard, the use rate exceeds 99.
cable After a two-month trial of the cable repaired according to the new standard, the use rate exceeds 99.
-
The life of SolarCity solar photovoltaic modules is more than 35 years
Time of Update: 2022-11-22
Solar PV modulesSolarCity said that the test results were certified by DNV GL, a third-party organization.
Solar PV modulesSolarCity said that the test results were certified by DNV GL, a third-party organization.
Solar PV modulesSolarCity said that the test results were certified by DNV GL, a third-party organization.
-
The third-generation nuclear power AP1000 in-shell cable passed the qualification
Time of Update: 2022-11-17
It was developed by the scientific research team of Shangshang Group after more than 3 years, after countless tests and verifications, and overcoming many technical difficulties, to meet a series of demanding requirements put forward by the design of the third-generation nuclear power plant system, including high electrical performance, low smoke and halogen-free flame retardant, 60-year life, resistance to high dose β, γ radiation irradiation, resistance to high parameter LOCA and long-term immersion after LOCA.
-
Zhenhai Refinery successfully developed new ultra-low ash high-end polypropylene products
Time of Update: 2022-10-18
A solid step On May 6, Zhenhai Refinery's No. 1 polypropylene plant used domestic high-activity catalysts for the first time, and successfully developed a new polypropylene product PPH-C03 for ultra-low ash electrical membranes, marking Zhenhai Refinery's high-end polypropylene products.
-
The State Food and Drug Administration will supervise the 2022 vaccine production inspection
Time of Update: 2022-10-14
Huang Guo stressed that the relevant departments and bureaus of the State Food and Drug Administration, directly subordinate and territorial drug regulatory departments should strengthen organizational leadership and coordination, further coordinate the national inspection force, optimize the inspection mode, strengthen the inspection means, and complete the annual full-coverage vaccine production inspection work with high quality and efficiency as planned.
-
Hot Spots The new urethral stent brings new hope for the treatment of BPH/LUTS
Time of Update: 2022-10-13
Benign prostatic hyperplasia (BPH) is an age-related progressive disease usually accompanied by bladder outflow tract obstruction and lower urinary tract symptoms (LUTS). Many minimally invasive surgi
-
"Collagen bricks" delay brain cancer regeneration and protect healthy tissues
Time of Update: 2022-10-02
The UC San Diego Health Center is the first hospital system in San Diego to offer a new, highly targeted and precisely targeted radiation therapy that protects the healthy tissue of brain cancer patients while delaying tumor regeneration.
-
Another pharmaceutical company disclosed the first three quarters of this year's performance pre-increase announcement
Time of Update: 2022-09-30
On September 26, Besmei released the first three quarters of 2022 performance forecast, it is expected that the net profit attributable to the shareholders of listed companies in the first three quarters of this year (referred to as net profit) will be about 106 million yuan - 119 million yuan, an increase of 141.
-
Responding to the voice of the industry with "food" force "2021FHC Shanghai Global Food Exhibition" ended
Time of Update: 2022-08-31
(PR Newswire) Responsible editor: Zhao Yu Review: Ouyang Meihua The 25th FHC Shanghai Global Food Exhibition, co-sponsored by Shanghai Catering and Cooking Industry Association and Shanghai Bohua International Exhibition Co.
-
Mengniu President Lu Minfang: Promote China's dairy industry from "bigger and stronger" to "excellent and refined
Time of Update: 2022-08-31
" Responsible editor: Wang Jinchen Review: Zheng Ying On July 18, the 12th China Dairy Industry Conference and 2021 China Dairy Industry Exhibition and China Dairy Industry Top 20 (D20) Summit were held in Hefei, Anhui Province .
-
The revision of the national standard for polypropylene meltblown special materials was officially launched
Time of Update: 2022-08-23
PP) The technical content in the draft of the national standard for meltblown special materials has been extensively discussed and exchanged, and the next revision work has been deployed and arranged At the video conference, the relevant person in charge of the Resin Application Research Institute of Yanshan Petrochemical (High-Tech Company) reported on the research, plan, sample collection, data collection, etc.
-
【Chinese Achievements】Professor Shen Lin from Beijing Cancer Hospital leads the International Research on Esophageal Cancer Weekly Report on Tumor Treatment
Time of Update: 2022-06-04
NEJM: Results from the AGILE trial confirm significant improvement in ivonib plus azacitidine compared with placebo plus azacitidine in patients with newly diagnosed IDH1-mutant acute myeloid leukemia who are ineligible for induction chemotherapy Event-free survival, remission and overall survival .
